- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05341297
A Transdiagnostic Internet Intervention for Parents of Children With Anxiety and Depressive Symptoms (ParentKIT)
September 12, 2023 updated by: Costina-Ruxandra Păsărelu, Babes-Bolyai University
Digital Parent-led Transdiagnostic Interventions for Child and Adolescent Anxiety and Depressive Disorders
The purpose of this study is to evaluate the efficacy of a transdiagnostic, parent-led, Internet-delivered intervention in reducing child and adolescent internalizing problems.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Anxiety and depressive symptoms are common in children and adolescents.
There is substantial research indicating that transdiagnostic Internet interventions are effective for adults and children with anxiety and depressive disorders; however, there is limited research on the efficacy of such programs aimed at parents of children and adolescents with anxiety and depressive symptoms.
This study aims to investigate the efficacy of a transdiagnostic Internet intervention for parents of children with elevated anxiety and depressive symptoms.
Study Type
Interventional
Enrollment (Actual)
111
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cluj-Napoca, Romania, 400015
- Babes-Bolyai University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 14 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- parent of a child/ adolescent aged 6 to 14 years
- elevated internalizing problems
- have Internet access
Exclusion Criteria:
- undergoing psychotherapy/ pharmacological treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ParentKIT
Transdiagnostic parent-led Internet-delivered intervention Participants in the experimental group will have access to the ParentKIT intervention.
The intervention was developed based on existing Cognitive Behavioral Therapy/ Rational Emotive Behavior Therapy protocols for parents of children with internalizing problems.
It consists of nine modules delivered over three weeks.
|
The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms.
The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
|
|
No Intervention: Waitlist
Participants in the waitlist condition will have access to the program after 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the brief Revised Children's Anxiety and Depression Scale - parent version
Time Frame: Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
Measure of child anxiety and depressive symptoms, as reported by parents.
Scores range between 0 and 33; higher scores indicate higher anxiety and depressive symptoms.
|
Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Patient Health Questionnaire-4
Time Frame: Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
Measure of anxiety and depressive symptoms - will be used to measure changes in parental distress.
Scores range between 0 and 12. Higher scores indicate higher distress.
|
Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
|
Change in the Parental Self-Efficacy Scale
Time Frame: Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
Measure of parental self-efficacy in relationship to parenting practices that may decrease anxiety and depression risks for adolescents.
Total scores range between and 9 and 36.
Higher scores indicate higher parental self-efficacy.
|
Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
|
Change in the Family Accommodation Scale
Time Frame: Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
Measure of parental anxiety accommodations.
Scores range between 0 and 52.
Higher scores indicate higher parental anxiety accommodations.
|
Baseline, 3 weeks and follow-up at 1 month after treatment termination
|
|
Satisfaction with the intervention
Time Frame: 3 weeks after treatment initiation
|
Client satisfaction will be measured with Client Satisfaction Questionnaire, short form (Attkisson & Zwick, 1982).
Scores range from 8 to 32, with higher scores indicating greater satisfaction with the intervention.
|
3 weeks after treatment initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Costina R Păsărelu, Ph.D, Babes-Bolyai University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2022
Primary Completion (Actual)
June 30, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
April 11, 2022
First Submitted That Met QC Criteria
April 16, 2022
First Posted (Actual)
April 22, 2022
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GTC 31371/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data will be uploaded after publication of the results.
IPD Sharing Time Frame
De-identified data will be uploaded after publication of the results.
IPD Sharing Access Criteria
Upon the completion of the study, de-identified datasets will be available from the corresponding author on reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Fondation FondaMentalGYNOVNot yet recruitingDepression | Depression in Adults | Depression DisorderFrance